DWA
UROV

Dorsey Wright & Associates’s Urovant Sciences Ltd. UROV Stock Holding History

Dorsey Wright & Associates’s Portfolio UROV Stock Details UROV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-790
Closed -$7K – 385
2020
Q1 		$7K Buy
+790
New +$9.51K ﹤0.01% 233

Other funds holding UROV

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
PHS
Pekin Hardy Strauss Chicago, Illinois $957M AUM 44.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BBVA
Banco Bilbao Vizcaya Argentaria Madrid, Spain $14.3B AUM 26.23% 1-Year Est. Return

Dorsey Wright & Associates's UROV Position: Q2 2020 in Review

Dorsey Wright & Associates sold out of Urovant Sciences Ltd. (UROV) in Q2 2020, closing a stake of 790 shares — an estimated $7K sold.

Dorsey Wright & Associates first reported a position in UROV in Q1 2020 and held it in 1 quarter. The position peaked at $7K in Q1 2020. 25 funds tracked by Wall St. Rank hold UROV as of Q2 2020.

  • Dorsey Wright & Associates reported no remaining Urovant Sciences Ltd. position as of Q2 2020 after selling out during the quarter.
  • Dorsey Wright & Associates sold 790 Urovant Sciences Ltd. shares in Q2 2020, an estimated $7K.
  • Dorsey Wright & Associates first reported a position in Urovant Sciences Ltd. in Q1 2020 and held it in 1 quarter.
  • Dorsey Wright & Associates's Urovant Sciences Ltd. position peaked at $7K in Q1 2020.
  • 25 funds tracked by Wall St. Rank held Urovant Sciences Ltd. as of Q2 2020.

Based on Dorsey Wright & Associates's 13F filing for Q2 2020, filed 23 Jul 2020.